Article Plan⁚ FabiSpray⁚ Mechanism of Action and Efficacy
Mechanism of Action
The enoyl-ACP reductase (FabI) enzyme is a well-validated target for anti-staphylococcal drug discovery and development. FabI inhibition disrupts the rate-determining step in bacterial fatty acid biosynthesis‚ offering a potential strategy against bacterial infections. Despite challenges in targeting Gram-negative bacteria‚ recent research has identified compounds like Debio-1452-NH3 with antibacterial activity against these pathogens. By understanding the physicochemical traits that aid in the accumulation of small molecules in Gram-negative bacteria‚ scientists have designed FabI inhibitors like fabimycin‚ showing enhanced antibacterial potency and specificity for pathogenic bacteria.
Efficacy
The efficacy of FabiSpray‚ a nitric oxide nasal spray‚ has been demonstrated through its antiviral properties targeting the COVID-19 virus in the upper airways. Utilizing its proven antimicrobial features‚ FabiSpray acts as a direct virucidal agent against SARS-CoV-2‚ providing a physical and chemical barrier over the nasal mucosa to prevent virus replication and spread to the lungs. The spray is priced nominally in India and has received accelerated approval for its efficacy in treating COVID-19 cases among adult patients based on phase-3 clinical trial results.
Leave a Reply